Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Scott C Wise"'
Autor:
Marcia Eisenberg, Shakti Ramkissoon, Mary K Nesline, Kyle C Strickland, Zachary D Wallen, Taylor J Jensen, Brian Caveney, Prasanth Reddy, Eric A Severson, Sheri Barnes, Scott C Wise
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ddad0baa65204710806cf7362fef87fe
Autor:
John S. Condeelis, Daniel L. Flynn, Joan G. Jones, Michele De Palma, Lawrence Chun, Yarong Wang, Maja H. Oktay, David Entenberg, Xiaoming Chen, Gada Al-Ani, Wei-Ping Lu, Cynthia B. Leary, Michael D. Kaufman, Molly M. Hood, Scott C. Wise, Ece Kadioglu, Bryan D. Smith, Jeanine Pignatelli, George S. Karagiannis, Allison S. Harney
Supplementary Material and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c83205cee26a7b12a2993be79368f6da
https://doi.org/10.1158/1535-7163.22507510
https://doi.org/10.1158/1535-7163.22507510
Autor:
Daniel L. Flynn, Michael Clare, Lance J. Stewart, Lawrence Chun, Karen M. Yates, Subha Vogeti, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Thiwanka Samarakoon, Thomas J. Rutkoski, William C. Patt, Tristan W. Patt, Wei-Ping Lu, Molly M. Hood, Carol L. Ensinger, Timothy M. Caldwell, R. John Booth, Yu Mi Ahn, Scott C. Wise, Benjamin A. Turner, Cynthia B. Leary, Michael D. Kaufman, Bryan D. Smith
Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1). Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but als
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a49f1af80ca00d7cc02eb5848964921
https://doi.org/10.1158/1535-7163.c.6536815.v1
https://doi.org/10.1158/1535-7163.c.6536815.v1
Autor:
John S. Condeelis, Daniel L. Flynn, Joan G. Jones, Michele De Palma, Lawrence Chun, Yarong Wang, Maja H. Oktay, David Entenberg, Xiaoming Chen, Gada Al-Ani, Wei-Ping Lu, Cynthia B. Leary, Michael D. Kaufman, Molly M. Hood, Scott C. Wise, Ece Kadioglu, Bryan D. Smith, Jeanine Pignatelli, George S. Karagiannis, Allison S. Harney
Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation, and metastasis, which can offset the effects of chemotherapy, radiation, and antiangiogenic therapy. Here, we show that the kinase switch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64e3696c40dea9ae99fa975de5b76e00
https://doi.org/10.1158/1535-7163.c.6538714.v1
https://doi.org/10.1158/1535-7163.c.6538714.v1
Autor:
Daniel L. Flynn, Michael Clare, Lance J. Stewart, Lawrence Chun, Karen M. Yates, Subha Vogeti, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Thiwanka Samarakoon, Thomas J. Rutkoski, William C. Patt, Tristan W. Patt, Wei-Ping Lu, Molly M. Hood, Carol L. Ensinger, Timothy M. Caldwell, R. John Booth, Yu Mi Ahn, Scott C. Wise, Benjamin A. Turner, Cynthia B. Leary, Michael D. Kaufman, Bryan D. Smith
Supplementary Materials and Methods. Supplementary table 1: XRay crystallography parameters for DP-4157/MET complex. Supplementary table 2: Source and description of kinases. Supplementary table 3: Selectivity of profile of altiratinib inhibition fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b914b7bf5b2f07136ac99e3d894850d
https://doi.org/10.1158/1535-7163.22501534
https://doi.org/10.1158/1535-7163.22501534
Autor:
Brian J. Druker, Thomas O'Hare, Michael W.N. Deininger, Daniel L. Flynn, Peter A. Petillo, Bryan D. Smith, Scott C. Wise, David J. Anderson, Mary Mac Partlin, Jeffrey W. Tyner, Lauren T. Adrian, Christopher A. Eide
Supplementary Tables 1-4, Figure 1 from The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a2432ac3c84471ba506f96d9dd9a62f
https://doi.org/10.1158/0008-5472.22392068
https://doi.org/10.1158/0008-5472.22392068
Autor:
Timothy M. Caldwell, Michael D. Kaufman, Scott C. Wise, Yu Mi Ahn, Molly M. Hood, Wei-Ping Lu, William C. Patt, Thiwanka Samarakoon, Lakshminarayana Vogeti, Subha Vogeti, Karen M. Yates, Stacie L. Bulfer, Bertrand Le Bourdonnec, Bryan Smith, Daniel Flynn
Publikováno v:
Bioorganicmedicinal chemistry letters. 74
Based on the structure of an early lead identified in Deciphera's proprietary compound collection of switch control kinase inhibitors and using a combination of medicinal chemistry guided structure activity relationships and structure-based drug desi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8349701859d67ece838c4aee93cdefb
https://pubmed.ncbi.nlm.nih.gov/35961461
https://pubmed.ncbi.nlm.nih.gov/35961461
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundBladder cancer (BC) is the thirteenth leading cause of cancer-related deaths.1 Five checkpoint immunotherapies that target the PD-1/PD-L1 axis are FDA approved, and gene- and protein-based approaches are helping to identify new combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed1e2e10d6122d50487637cb0867b44
https://doaj.org/article/72996a69f8a1464ca19e1ccb1c873d3c
https://doaj.org/article/72996a69f8a1464ca19e1ccb1c873d3c
Autor:
Timothy M. Caldwell, Yu Mi Ahn, Stacie L. Bulfer, Cynthia B. Leary, Molly M. Hood, Wei-Ping Lu, Lakshminarayana Vogeti, Subha Vogeti, Michael D. Kaufman, Scott C. Wise, Bertrand Le Bourdonnec, Bryan Smith, Daniel Flynn
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 74:128928
Based on knowledge of kinase switch-control inhibition and using a combination of structure-based drug design and standard medicinal chemistry principles, we identified a novel series of dihydropyrimidone-based CSF1R kinase inhibitors displaying exqu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edc653f661a2cabdb62b653e9090e45f
https://doi.org/10.1016/j.bmcl.2022.128928
https://doi.org/10.1016/j.bmcl.2022.128928
Autor:
Scott C. Wise, Gege Tan, Wei-Ping Lu, Michael Kaufman, Breelyn A. Wilky, Subha Vogeti, Yu Mi Ahn, Daniel L. Flynn, Rodrigo Ruiz-Soto, Bryan D. Smith, Maitreyi Sharma, Timothy M. Caldwell, Lakshminarayana Vogeti, Cynthia B. Leary, Lara E. Davis
Publikováno v:
Molecular cancer therapeutics. 20(11)
Macrophages can be co-opted to contribute to neoplastic, neurologic, and inflammatory diseases. Colony-stimulating factor 1 receptor (CSF1R)-dependent macrophages and other inflammatory cells can suppress the adaptive immune system in cancer and cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65c006910ab2e7cfee88acd2edb635d5
https://pubmed.ncbi.nlm.nih.gov/34433663
https://pubmed.ncbi.nlm.nih.gov/34433663